Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
KL
Kalaris Therapeutics, Inc. Common Stock
KLRS
Mkt Cap
$48.3M
Volume
44.61K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
KL
KLRS
KL
Kalaris Therapeutics, Inc. Common Stock
KLRS
News
·
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Mkt Cap
$52.1M
Volume
44.61K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Insider
Filings
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Kalaris Therapeutics (Nasdaq: KLRS), a clinical-stage biopharmaceutical company, announced that management will participate in a Fireside Chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The company is developing TH103, a dual-action anti-VEGF therapeutic, currently in Phase 1b/2 trials for neovascular Age-related Macular Degeneration (nAMD), with preliminary data expected in the first half of 2027.
GlobeNewswire Inc. · Aug 31, 2026
SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholders
Abbott Cooper PLLC is investigating potential fiduciary duty breaches by the board of directors of Stablecoin Development Corporation (formerly NovaBay Pharmaceuticals, Inc.). The investigation targets stockholders who continuously held shares since prior to August 19, 2025. Similar investigations are also underway for Kalaris Therapeutics (formerly AlloVir) and Abundia Global Impact Group (formerly Houston American Energy Corp.).
GlobeNewswire Inc. · Aug 4, 2026
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Kalaris Therapeutics announced positive Phase 1a data for TH103, its investigational treatment for neovascular AMD. The expanded trial of 17 treatment-naive patients showed improvements in vision and retinal anatomy, with 29% requiring no additional anti-VEGF treatment during six-month follow-up. TH103 demonstrated 27-53 fold lower plasma levels compared to leading anti-VEGF agents while maintaining efficacy. The company is actively enrolling patients in Phase 1b/2 trials with preliminary data expected in H1 2027.
GlobeNewswire Inc. · Jul 17, 2026
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
Kalaris Therapeutics announced it will present Phase 1a clinical data for TH103, a novel dual-targeting VEGF/HSPG biologic, at the American Society of Retina Specialists 2026 Annual Meeting on July 17, 2026. The company's Phase 1b/2 multiple ascending dose study for neovascular age-related macular degeneration is actively enrolling patients, with initial data expected in the first half of 2027.
GlobeNewswire Inc. · Jun 23, 2026
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
Kalaris Therapeutics secured a $50 million private placement with institutional investors to advance clinical development of TH103 for neovascular AMD, with funds expected to support operations through Q3 2027.
GlobeNewswire Inc. · Dec 17, 2025
Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates
Kalaris Therapeutics reported Q2 2025 financial results, continuing enrollment in a Phase 1 trial for TH103, a novel anti-VEGF treatment for retinal diseases. The company has $88.4M in cash, expects initial clinical data in Q4 2025, and reported a net loss of $11.4 million for the quarter.
GlobeNewswire Inc. · Aug 13, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
KL
KLRS
Kalaris Therapeutics, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
KLRS
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any KLRS yet.
Related Tickers
Earnings